Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Plerixafor for Stem Cell Mobilization in Normal Donors
NCT01818284Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Oct 2013
- Primary completion
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of plerixafor in hematopoietic stem cell transplantation (HSCT), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Donor Safety in Mobilizing Peripheral Blood Progenitor Cells (PBPC) at 5 days and Number of Donors Reaching Stem Cell Target Collection on First Day of Collection at 4 days. Started Oct 2013; status: completed.
02
Drugs
plerixafor
03
Conditions
hematopoietic stem cell transplantation (HSCT)
Beyond the preview
Go deeper on NCT01818284.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01818284.